Aerie Pharma (AERI) Misses Q4 EPS by 11c

Aerie Pharma (NASDAQ: AERI) reported Q4 EPS of ($1.38), $0.11 worse than the analyst estimate of ($1.27).

As of December 31, 2017, Aerie had cash, cash equivalents and investments of $249.7 million. For the fourth quarter ended December 31, 2017, Aerie reported a GAAP net loss of $58.5 million, or $1.60 loss per share, compared to a net loss of $29.3 million and $0.87 loss per share for the fourth quarter of 2016. The weighted average number of shares outstanding utilized in the calculation of net loss per share was 36,487,669 and 33,613,375 for the fourth quarters of 2017 and 2016, respectively. Total shares outstanding as of December 31, 2017 were 36,947,637.

For earnings history and earnings-related data on Aerie Pharma (AERI) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance
• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance